XML 18 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Prepaid Drug Product for Testing
9 Months Ended
Sep. 30, 2017
Prepaid Drug Product For Testing [Abstract]  
Prepaid Drug Product for Testing
3.
Prepaid Drug Product for Testing
 
Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future clinical development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company made payments to its contract drug manufacturing and raw material suppliers totaling $0.4 million in late 2015 and all of 2016 pursuant to drug supply contracts for the manufacture and delivery of prexigebersen for testing in a Phase II clinical trial. This amount was carried on the Balance Sheet as of December 31, 2016 at cost as Prepaid Drug Product for Testing. The Company recognized certain expenses and incurred additional installment costs during 2017, with advanced payments totaling $0.7 million, which are carried on the Balance Sheet as of September 30, 2017 as Prepaid Drug Product for Testing (See Note 11).